Prelude Therapeutics Prices $90M Equity Offering
Prelude Therapeutics (PRLD) has priced a public offering of over 18 million shares of its voting common stock at $4.44 each, along with pre-funded warrants for up to 2.25 million additional shares. The gross proceeds from the offering are estimated to be around $90 million. The offering is expected to provide the company with capital for research and development and general corporate purposes.
Topics: equity offering funding stock issuance